+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market Forecast to 2033- Product Image
Biosimilars Market Forecast to 2033- Product Image
New

Biosimilars Market Forecast to 2033

  • PDF Icon

    Report

  • 150 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 4613404
REQUEST CUSTOMIZATION
Description Jump to:
The global biosimilars market size was estimated at USD 33.92 million in 2024 and is projected to reach USD 151.58 million by 2033, growing at a CAGR of 18.27% from 2025 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth.

In addition, these drugs are comparatively easy to produce since they require less investment in research and development while providing similar results. This can help cut down expenditures on health. Moreover, the reduction in production costs and increasing demand can encourage producers to shift to biosimilars due to increased profits, which can give a further boost to this market. Biosimilars may contain slightly different substances and combinations of medical ingredients, but they are considered similar to their reference biologics in terms of effectiveness and safety.

Several regulations are in place to assess the compatibility and safety of biosimilar drugs. For instance, the FDA’s Abbreviated New Drug Application Process requires applicants to scientifically prove that the performance of their product is similar to the reference biologics. It can be demonstrated by proving that their product takes a similar time to reach the bloodstream as the original product. Such regulations can help build trust in these drugs and expand their market share.

Moreover, the increasing prevalence of chronic or non-communicable diseases across the globe is also expected to drive the market. According to statistics released by the World Health Organization in November 2023, non-communicable diseases, such as cancer, diabetes, and heart diseases, cause 41 million deaths every year, out of which 77% of fatalities belong to low- and middle-income countries.

The U.S. FDA approved three cancer-related biosimilars in 2022, which are expected to hit the market in 2023. These growing opportunities in this market are also encouraging key players to increase their investment in the research and development of biosimilars. For instance, according to an article published in Business Today in April 2022, Biocon Biologics planned to increase its R&D expenses by 10% to 15% to advance its pipeline of biosimilar molecules. The step is expected to help strengthen its future position in the market. There is a boom in the pharmaceutical industry in the development of biosimilar medications.

Global Biosimilars Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global biosimilars market report based on drug class, indication, end use and region:

Drug Class Outlook (Revenue, USD Billion, 2021-2033)

  • Monoclonal Antibodies (mAbs)
  • Growth Factors & Hematopoietic Agents
  • Insulin & Analogues
  • Osteoporosis / Bone Metabolism Agents
  • Others

Indication Outlook (Revenue, USD Billion, 2021-2033)

  • Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
  • Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
  • Diabetes Mellitus (Type 1 & Type 2)
  • Ophthalmic Disorders (Wet AMD, DME, RVO)
  • Hematologic / Rare Blood Disorders
  • Others

End Use Outlook (Revenue, USD Billion, 2021-2033)

  • Hospitals
  • Specialty Pharmacies
  • Online & Retail Channels

Regional Outlook (Revenue, USD Billion, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Indication
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Biosimilars Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Biosimilars Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
4.4. Monoclonal Antibodies (mAbs)
4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021-2033 (USD Billion)
4.5. Growth Factors & Hematopoietic Agents
4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021-2033 (USD Billion)
4.6. Insulin & Analogues
4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021-2033 (USD Billion)
4.7. Osteoporosis / Bone Metabolism Agents
4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021-2033 (USD Billion)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2021-2033 (USD Billion)
Chapter 5. Biosimilars Market: Indication Business Analysis
5.1. Indication Market Share, 2024 & 2033
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021-2033 (USD Billion)
5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021-2033 (USD Billion)
5.6. Diabetes Mellitus (Type 1 & Type 2)
5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021-2033 (USD Billion)
5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021-2033 (USD Billion)
5.8. Hematologic / Rare Blood Disorders
5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021-2033 (USD Billion)
5.9. Others
5.9.1. Others Market Estimates and Forecasts, 2021-2033 (USD Billion)
Chapter 6. Biosimilars Market: End Use Business Analysis
6.1. End Use Market Share, 2024 & 2033
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
6.4. Hospitals
6.4.1. Hospitals Market Estimates and Forecasts, 2021-2033 (USD Billion)
6.5. Specialty Pharmacies
6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021-2033 (USD Billion)
6.6. Online & Retail Channels
6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021-2033 (USD Billion)
Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Biosimilars Market Estimates and Forecasts, by Country, 2021-2033 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Type Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Type Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Type Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5. Europe
7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Type Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Type Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Type Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Type Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Type Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Type Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Type Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Type Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Type Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Type Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Type Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Type Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Type Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Type Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.7. Latin America
7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Type Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Type Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Type Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Type Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Type Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Type Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021-2033 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Amgen Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. F Hoffman-La Roche Ltd
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Sandoz International GmbH
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Dr. Reddy’s Laboratories
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Teva Pharmaceutical Industries Ltd
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Pfizer Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Samsung Biopis
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Biocon
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Viatris Inc.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Celltrion Healthcare Co.Ltd
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. AbbVie Inc.
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Biosimilars Market, by Region, 2021-2033 (USD Billion)
Table 4 Global Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 5 Global Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 6 Global Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 7 North America Biosimilars Market, by Country, 2021-2033 (USD Billion)
Table 8 North America Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 9 North America Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 10 North America Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 11 US Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 12 US Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 13 US Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 14 Canada Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 15 Canada Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 16 Canada Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 17 Mexico Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 18 Mexico Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 19 Mexico Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 20 Europe Biosimilars Market, by Country, 2021-2033 (USD Billion)
Table 21 Europe Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 22 Europe Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 23 Europe Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 24 UK Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 25 UK Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 26 UK Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 27 Germany Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 28 Germany Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 29 Germany Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 30 France Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 31 France Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 32 France Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 33 Italy Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 34 Italy Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 35 Italy Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 36 Spain Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 37 Spain Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 38 Spain Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 39 Norway Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 40 Norwa Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 41 Norwa Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 42 Denmark Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 43 Denmark Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 44 Denmark Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 45 Sweden Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 46 Swede Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 47 Swede Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 48 Asia-Pacific Biosimilars Market, by Country, 2021-2033 (USD Billion)
Table 49 Asia-Pacific Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 50 Asia-Pacific Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 51 Asia-Pacific Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 52 Japan Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 53 Japan Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 54 Japan Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 55 China Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 56 China Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 57 China Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 58 India Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 59 India Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 60 India Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 61 Australia Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 62 Australia Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 63 Australia Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 64 South Korea Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 65 South Korea Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 66 South Korea Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 67 Thailand Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 68 Thailand Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 69 Thailand Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 70 Latin America Biosimilars Market, by Country, 2021-2033 (USD Billion)
Table 71 Latin America Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 72 Latin America Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 73 Latin America Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 74 Brazil Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 75 Brazil Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 76 Brazil Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 77 Argentina Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 78 Argentina Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 79 Argentina Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 80 Middle East & Africa Biosimilars Market, by Country, 2021-2033 (USD Billion)
Table 81 Middle East & Africa Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 82 Middle East & Africa Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 83 Middle East & Africa Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 84 South Africa Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 85 South Africa Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 86 South Africa Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 87 Saudi Arabia Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 88 Saudi Arabia Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 89 Saudi Arabia Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 90 UAE Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 91 UAE Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 92 UAE Biosimilars Market, by End Use, 2021-2033 (USD Billion)
Table 93 Kuwait Biosimilars Market, by Drug Class, 2021-2033 (USD Billion)
Table 94 Kuwait Biosimilars Market, by Indication, 2021-2033 (USD Billion)
Table 95 Kuwait Biosimilars Market, by End Use, 2021-2033 (USD Billion)
List of Figures
Figure 1 Biosimilars market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and disease outlook (USD Billion)
Figure 10 Competitive landscape
Figure 11 Biosimilars market dynamics
Figure 12 Biosimilars market: Porter’s five forces analysis
Figure 13 Biosimilars market: PESTLE analysis
Figure 14 Drug Class market, 2021-2033 (USD Billion)
Figure 15 Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021-2033 (USD Billion)
Figure 16 Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021-2033 (USD Billion)
Figure 17 Insulin & Analogues Market Estimates and Forecasts, 2021-2033 (USD Billion)
Figure 18 Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021-2033 (USD Billion)
Figure 19 Others Market Estimates and Forecasts, 2021-2033 (USD Billion)
Figure 20 Indication market estimates and forecasts, 2021-2033 (USD Billion)
Figure 21 Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) market estimates and forecasts, 2021-2033 (USD Billion)
Figure 22 Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) market estimates and forecasts, 2021-2033 (USD Billion)
Figure 23 Diabetes Mellitus (Type 1 & Type 2) market estimates and forecasts, 2021-2033 (USD Billion)
Figure 24 Ophthalmic Disorders (Wet AMD, DME, RVO) market estimates and forecasts, 2021-2033 (USD Billion)
Figure 25 Hematologic / Rare Blood Disorders market estimates and forecasts, 2021-2033 (USD Billion)
Figure 26 Others market estimates and forecasts, 2021-2033 (USD Billion)
Figure 27 End Use market estimates and forecasts, 2021-2033 (USD Billion)
Figure 28 Hospitals market estimates and forecasts, 2021-2033 (USD Billion)
Figure 29 Specialty Pharmacies market estimates and forecasts, 2021-2033 (USD Billion)
Figure 30 Online & Retail Channels market estimates and forecasts, 2021-2033 (USD Billion)
Figure 31 Biosimilars market revenue, by region
Figure 32 Regional marketplace: Key takeaways
Figure 33 North America biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 34 US country dynamics
Figure 35 US biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 36 Canada country dynamics
Figure 37 Canada biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 38 Mexico country dynamics
Figure 39 Mexico biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 40 Europe biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 41 UK country dynamics
Figure 42 UK biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 43 Germany country dynamics
Figure 44 Germany biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 45 France country dynamics
Figure 46 France biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 47 Italy country dynamics
Figure 48 Italy biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 49 Spain country dynamics
Figure 50 Spain biosimilars market, 2021-2033 (USD Billion)
Figure 51 Norway country dynamics
Figure 52 Norway biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 53 Sweden country dynamics
Figure 54 Sweden biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 55 Denmark country dynamics
Figure 56 Denmark biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 57 Asia-Pacific biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 58 Japan country dynamics
Figure 59 Japan biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 60 China country dynamics
Figure 61 China biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 62 India country dynamics
Figure 63 India biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 64 Australia country dynamics
Figure 65 Australia biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 66 South Korea country dynamics
Figure 67 South Korea biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 68 Thailand country dynamics
Figure 69 Thailand biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 70 Latin America biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 71 Brazil country dynamics
Figure 72 Brazil biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 73 Argentina country dynamics
Figure 74 Argentina biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 75 MEA biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 76 South Africa country dynamics
Figure 77 South Africa biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 78 Saudi Arabia country dynamics
Figure 79 Saudi Arabia biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 80 UAE country dynamics
Figure 81 UAE biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 82 Kuwait country dynamics
Figure 83 Kuwait biosimilars market estimates and forecasts, 2021-2033 (USD Billion)
Figure 84 Company categorization
Figure 85 Company market position analysis
Figure 86 Strategic framework

Companies Mentioned

The companies profiled in this Biosimilars market report include:
  • Amgen Inc.
  • F Hoffman-La Roche Ltd.
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Samsung Biopis
  • Biocon
  • Viatris Inc.
  • Celltrion Healthcare Co., Ltd.
  • AbbVie Inc.

Table Information

Report AttributeDetails
No. of Pages150
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 33.92 Million
Forecasted Market Value ( USD ) by 2033 $ 151.58 Million
Compound Annual Growth Rate18.2%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report by Source (Mammalian, Non-mammalian), Therapeutic Area (Oncology, Blood Disorders), Service, and Region with Growth Forecasts, 2025-2033 - Product Image

Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report by Source (Mammalian, Non-mammalian), Therapeutic Area (Oncology, Blood Disorders), Service, and Region with Growth Forecasts, 2025-2033

  • Report
  • 180 Pages
  • Global
From
Biosimilars - Global Strategic Business Report - Product Image

Biosimilars - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Biosimilar Contract Manufacturing - Global Strategic Business Report - Product Image

Biosimilar Contract Manufacturing - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Biosimilars Market Outlook, 2030 - Product Image

Biosimilars Market Outlook, 2030

  • Report
  • 191 Pages
  • Global
From
Biosimilars Market Overview, 2025-30 - Product Image

Biosimilars Market Overview, 2025-30

  • Report
  • 102 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.